share_log

Oramed Pharmaceuticals Analyst Ratings

Benzinga Analyst Ratings ·  Jan 12, 2023 19:51
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/12/2023 Canaccord Genuity Downgrades Buy → Hold
05/16/2022 178.04% Aegis Capital $35 → $30 Maintains Buy
02/18/2022 85.36% Cantor Fitzgerald → $20 Initiates Coverage On → Overweight
11/30/2021 196.57% HC Wainwright & Co. $17 → $32 Maintains Buy
11/29/2021 196.57% HC Wainwright & Co. $17 → $32 Maintains Buy
11/02/2021 224.37% Aegis Capital $20 → $35 Maintains Buy
07/29/2021 178.04% Canaccord Genuity $27 → $30 Maintains Buy
06/08/2021 85.36% Aegis Capital $12 → $20 Maintains Buy
04/20/2021 150.23% Canaccord Genuity → $27 Initiates Coverage On → Buy
02/09/2021 113.16% National Securities Corporation → $23 Initiates Coverage On → Buy
01/27/2021 11.21% Aegis Capital $6 → $12 Maintains Buy
07/13/2020 57.55% HC Wainwright & Co. $16 → $17 Reiterates → Buy
06/22/2020 48.29% HC Wainwright & Co. $20 → $16 Maintains Buy
09/11/2019 -35.13% Ladenburg Thalmann → $7 Initiates Coverage On → Buy

What is the target price for Oramed Pharmaceuticals (ORMP)?

The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by Cantor Fitzgerald on February 18, 2022. The analyst firm set a price target for $20.00 expecting ORMP to rise to within 12 months (a possible 85.36% upside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?

The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by Cantor Fitzgerald, and Oramed Pharmaceuticals initiated their overweight rating.

When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on February 18, 2022 so you should expect the next rating to be made available sometime around February 18, 2023.

Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?

While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a initiated with a price target of $0.00 to $20.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $10.79, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment